Lantheus Holdings (LNTH) Liabilities and Shareholders Equity (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Liabilities and Shareholders Equity of $2.3 billion for Q1 2026, up 14.18% YoY from $2.1 billion in Q1 2025, and up 5.35% sequentially from $2.2 billion in Q4 2025.
Lantheus Holdings (LNTH) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
Lantheus Holdings has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $2.3 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 14.18% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $9.0 billion (up 11.73% YoY), while the FY2025 annual figure was $2.2 billion, up 12.48% from the prior year.
- Liabilities and Shareholders Equity advanced to $2.3 billion in Q1 2026, from $2.2 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for LNTH reached as high as $2.3 billion in Q1 2026 and fell as low as $933.2 million in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $1.8 billion (2024), against an average of $1.7 billion.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 52.96% — and 2025, when it increased 9.09%.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.3 billion in 2022, then grew by 24.97% to $1.7 billion in 2023, then climbed by 19.94% to $2.0 billion in 2024, then grew by 12.48% to $2.2 billion in 2025, then grew by 5.35% to $2.3 billion in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $2.3 billion, $2.2 billion, and $2.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.67 Bn | 34.93 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 30.59 Bn | 28.65 Bn | 1.62 Bn | 15.15 Bn |
| 3 | RedHill Biopharma | 26.22 Bn | 26.22 Bn | - | - |
| 4 | United Therapeutics | 23.80 Bn | 21.65 Bn | 648.10 Mn | 6.71 Bn |
| 5 | Curaleaf Holdings | 23.70 Bn | 23.70 Bn | 157.29 Mn | - |
| 6 | Viatris | 18.69 Bn | 16.89 Bn | 1.16 Bn | 36.83 Bn |
| 7 | Neurocrine Biosciences | 16.86 Bn | 15.54 Bn | 800.70 Mn | 4.91 Bn |
| 8 | Elanco Animal Health | 11.99 Bn | 11.57 Bn | 785.00 Mn | 13.22 Bn |
| 9 | Dr Reddys Laboratories | 11.65 Bn | 11.51 Bn | - | 6.18 Bn |
| 10 | Lantheus Holdings | 78.78 Mn | -419.80 Mn | 230.92 Mn | 2.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.35 Bn |
| Dec 31, 2025 | 2.23 Bn |
| Sep 30, 2025 | 2.28 Bn |
| Jun 30, 2025 | 2.12 Bn |
| Mar 31, 2025 | 2.06 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Sep 30, 2024 | 2.05 Bn |
| Jun 30, 2024 | 1.94 Bn |
| Mar 31, 2024 | 1.83 Bn |
| Dec 31, 2023 | 1.65 Bn |
| Sep 30, 2023 | 1.52 Bn |
| Jun 30, 2023 | 1.34 Bn |
| Mar 31, 2023 | 1.35 Bn |
| Dec 31, 2022 | 1.32 Bn |
| Sep 30, 2022 | 1.10 Bn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 933.17 Mn |
| Dec 31, 2021 | 863.78 Mn |
| Sep 30, 2021 | 847.82 Mn |
| Jun 30, 2021 | 857.80 Mn |